Pamela D. Garzone, Ph.D.

Pamela D. Garzone is a respected pharmaceutical executive with a significant record of achievement in drug development and leadership, ascending to the level of Chief Medical Officer. She has led teams successfully through the regulatory process, culminating in the clearance of multiple INDs in different therapeutic areas and approval of registration dossiers. Pamela is valued as an authentic leader, providing inspiration and motivation,  mediating conflict resolution, and was the chief influencer of executive management. She has interacted with health authorities (US, CHMP, PMDA, HC) for pre-IND meetings, EOP2 meetings, FDA advisory committees, and EMEA scientific advice meetings. Pamela is an invited speaker at international meetings and for prominent organizations as well as an author of peer-reviewed scientific articles. Recognized for her strategic, scientific, and regulatory leadership in drug development, she serves as an advisor to executives of start-up and clinical-stage biotechnology companies, venture capitalists, and non-profit research foundations and as the co-chair of AIM-HI Women’s Venture Competition. She has extensive experience helping boards and committees achieve aggressive goals and fulfill key objectives.

Pamela was most recently the Chief Medical Officer of Calibr, a division of Scripps Research. Prior to joining Calibr, Pamela spent ten years at Pfizer (2009-2019), located in South San Francisco, CA. Before she retired from Pfizer, she was Vice President, Group Asset Team Lead, serving on multiple leadership teams in an early oncology clinical research department. From 2006 to 2009, Pamela was Senior Director of Clinical Development at Elan Pharmaceuticals, focusing on early-stage assets in neurodegenerative and autoimmune diseases.

In the early years of her industrial career, Pamela created her pathway to leadership- managing preclinical groups such as toxicology and pharmacokinetic and drug metabolism functions in addition to planning and developing protocols for clinical pharmacology studies. During this time, she authored or co-authored at least a dozen IND submissions and 2 BLA submissions, including recombinant Factor Nine (FIX ) achieving revenues exceeding $500M since its approval. Pamela was selected as the industry representative to PhRMA and chairwoman of the Educational Committee of AAPS.

Pamela has taught undergraduate and graduate students, providing courses in clinical research, experimental design, and clinical pharmacology, while a faculty member of the School of Pharmacy at the University of Pittsburgh.

Pamela earned a Ph.D. in Clinical Science and M.Sc. in Pharmacy from the University of Pittsburgh and a B.Sc. in Pharmacy from Purdue University. She also obtained 2 certificates from Harvard University- the first one in Special Studies Administration and Management and Women on Boards from Harvard University. In addition, she received a certificate in Non-Profit Board Governance from the College of San Mateo in California.